A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamide

Harshraj Leuva,Keith Sigel,Mengxi Zhou,Julia Wilkerson,David H. Aggen,Yeun-Hee Anna Park,Christopher B. Anderson, Ta-Chueh Melody Hsu,Erik Langhoff, Glen McWilliams,Charles G. Drake,Richard Simon,Susan E. Bates,Tito Fojo

Seminars in Oncology（2019）

Cited 14|Views44

No score

Abstract

Background: With 1.3 million new cases in 2018 worldwide, prostate cancer remains a challenge. Development of novel therapies targeting the androgen pathway followed recognition of the continued importance of androgens in castrate-resistant prostate cancer. To assess abiraterone and enzalutamide efficacy we analyzed data from US Veterans Administration Medical Centers (VAMCs).

Translated text

Key words

Prostate cancer,Real-world data,Veterans Administration,VINCI,African Americans,Abiraterone,Enzalutamide,Health care disparities,Data warehouses,CRPC,Growth rate

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined